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Abstract
Introduction: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-
operative follow-up of patients with medullary thyroid carcinoma (MTC).
In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time
(DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT
have prognostic value in MTC patients.
Patients and methods: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In
total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into
the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox
proportional hazard method.
Results: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for
recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04).
Conclusions: The calcitonin and carcinembrional antigen doubling times of less than two years are negative
prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They
may be used as predictive factors for more intensive search of disease localization in asymptomatic
hypercalcitoninemia and for therapy choice in symptomatic disease.
Introduction
Medullary thyroid carcinoma (MTC) originates from
thyroid C-cells. The most important way of it’st r e a t -
ment is total surgical excision of thyroid gland accompa-
nied routinely by bilateral central lymphadenectomy
and, if necessary, by lateral neck lymph node dissection
[1]. In the postoperative follow-up, neck ultrasonogra-
phy accompanied by the calcitonin (Ct) and carcinoem-
brional antigen (CEA) serum level monitoring is used.
Especially Ct but also CEA assessments are so sensitive,
that elevated markers’ serum concentration can be
observed much earlier than a metastatic focus can be
visualized by imaging. It has been estimated that the Ct
serum level of 1000 pg/ml, which is 100 times the upper
normal value limit, indicates on 1 ml of tumor tissue,
although this ratio is variable [2]. Nevertheless, Ct esti-
mation is a good measure of tumor volume.
Elevated plasma Ct levels and more rarely serum CEA
concentration in some patients remain stable through-
out several years, whereas in others they raise rapidly.
The dynamics of these changes can be assessed by cal-
culating the time, they need to double - their doubling
time (DT). In the literature this parameter is considered
as having important prognostic value in postoperative
patients with MTC. One of the first publications in
which the prognostic value of Ct DT was assessed was
the study of Miyauchi i wsp. [3], where they found that
in contrast to preoperative Ct serum level, Ct DT had
an important prognostic role in overall and disease free
survival prediction. Barbet et al. [4] reported that Ct and
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than TNM or EORTC staging. Giraudet et al. [5] proved
that contrary to absolute Ct and CEA concentrations it
w a sC ta n dC E AD Tt h a tw a ss i g n i f i c a n t l yc o r r e l a t e d
w i t ht h er i s ko fp r o g r e s s i o na c c o r d i n gt ot h eR E C I S T
criteria. In the recently published meta-analysis, Meijer
et al. [6] found Ct and CEA DT as significant risk fac-
tors for recurrence and death due to MTC. The authors
used several cut-off values to classify patients as high-
or low-risk and the greatest prognostic value was
observed for the cut-off value of 1 year. What is inter-
esting, they reported greater prognostic value for CEA
DT compared to Ct DT.
Patients and methods
We observed retrospectively 110 patients followed up in
the Department of Nuclear Medicine and Endocrine
Oncology in the Institute of Oncology, Gliwice Branch,
Poland during the years 2004-2005. The Ct and CEA
concentration dynamics was analyzed from the diagnosis
until the most recent control visit. In 40 patients (36%)
the markers never exceeded the upper limit of normal
values. In the remaining 70 patients either Ct or CEA
and frequently both were elevated. For these patients
the DTs were calculated.
Plasma Ct concentration was assayed using the IRMA
hCT kit (Cis-Bio International, Gif-sur-Yvette, France)
(detection limit 1.5 pg/ml; normal range < 10 pg/ml;
expected linearity up to 1500 pg/ml). Appropriate dilu-
tions were prepared for concentrations above 200 pg/ml.
CEA was measured with ARCHITECT 8200 CEA Reagent
kit (Abbott, Il, USA) (sensitivity 0.5 ng/ml; normal range
<5 ng/ml; expected linearity up to 1500 ng/ml).
For each patient the DTs were calculated upon the b
parameter in the exponential regression equation c = a
exp(b*t), where c is concentration and t is time. The DT
value is equal to DT = ln 2/b, where ln 2 is the natural
logarithm of 2. DT unit is the same as of time. DTs
were calculated for each marker separately and the less
favorable DT was specified for each patient.
Overall survival and disease-free survival was visua-
lized on Kaplan-Meier plots and compared using Cox
proportional hazard model between groups that had Ct
DT, CEA DT or less-favorable DT positive and less than
2 years (group 1) versus negative or more than 2 years
(group 2).
Results
After initial total thyroidectomy (and lymph node dis-
section, when indicated) the concentration of both mar-
kers remained within normal range in 40 (36%) patients
during follow-up. In the remaining group of 70 patients
there were 46 women and 24 men. The median age at
initial diagnosis was 45.5 years, it ranged from 13.4 to
74.2 years. Within that group in 24 patients sporadic
MTC was diagnosed on the basis of RET diagnostics in
germ-line DNA, in 16 hereditary MTC was diagnosed,
whereas in 30 the genetic background is still being diag-
nosed or was unknown due to the lack of patient’sc o n -
sent. Median follow-up time was 8.25 years, ranging
from 1.48 to 20.03 years. During follow-up, in 45
patients recurrence was confirmed and 23 patients died.
During the observation period significant change in
DT value was noticed in no patient.
The most and the least-favorable Ct DTs was -0,65
and 0.13 years, respectively, with the 1/DT median value
reflecting the DT of 4.34 years. For the CEA the respec-
tive values were -0.74, 0.11 and 4.84 years, respectively.
There was a significant correlation between the
inverse values of Ct DT and CEA DT (p < 0.0001, R
2 =
0.60, slope = 0.713, Figure 1).
There was a significant difference between the groups
distinguished upon Ct, CEA and less-favorable marker
doubling times, both for overall survival, HR = 6.83
(2.92-15.97) p < 0.00001; HR = 4.22 (1.80-9.90) p =
0.0009 and HR = 8.99 (3.51-23.04) p < 0.00001, respec-
tively (Figure 2.), and for disease-free survival HR =
2.60 (1.41-4.81) p = 0.002; HR = 2.29 (1.20-4.40) p =
0.012 and HR = 2.61 (1.43-4.71) p = 0.0017, respectively
(Figure 3). The greatest hazard ratios were obtained for
the classification based upon the less-favorable DT.
Group 1 in all classifications showed greater risk for
death or recurrence. After 5 and 10 years of observation
in groups distinguished upon less-favorable DT the rates
were for group 1: 34.9 and 13.0% for recurrence-free
survival and 66.3 and 29.1% for overall survival, respec-
tively and for group 2: 66.6 and 47.5% for recurrence-
Figure 1 The correlation between inverse values of Ct and CEA
DT (progression rates; p < 0.0001, R2 = 0.60, slope = 0.713).
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respectively. In the high-risk group, there were 4
patients with DT < 0.5 year, who all died before 5 years
from diagnosis.
Discussion
We analyzed the time-course of Ct and CEA concentra-
tions in a group of surgically treated MTC patients fol-
lowed up in a single institution. We consider the group
Figure 2 Kaplan-Meier curves showing overall survival (A-C)
between groups classified upon Ct DT (A), CEA DT (B) and
less-favorable marker DT (C).
Figure 3 Kaplan-Meier curves showing disease-free survival (A-
C) between groups classified upon Ct DT (A), CEA DT (B) and
less-favorable marker DT (C).
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after the diagnosis, most of them are referred to our
centre from several surgical clinics. For the majority of
patients, the primary surgical treatment was outside our
centre, however, after the referral the subsequent fol-
low-up was conducted according to the strict rules
resembling recently published ATA guidelines [1]. Ct
and CEA estimations were performed at regular fre-
quency, at least yearly, using the same method. Follow-
ing detection of raised Ct and/or CEA level imaging was
instituted, encompassing neck sonography, chest and
abdominal CT and in rare occasions MR, scintigraphies
and PET scans. The results obtained in our population
regarding the risk of MTC recurrence are in good con-
cordance with that published by Meijer et al. [6]. They
reported recurrence HR of 2.90 (1.16-7.21) for the same
classification of Ct DT as in our group. Their results
concerning CEA DT hazard ratio of 4.73 (1.49-14.97)
are higher than ours, but they assessed CEA DT in only
38 of their 73 patients. Their HR for total survival is
also higher than in our population because they ana-
lyzed tumor-specific death, whereas such information
was not available for our patients at this preliminary
analysis.
CEA is generally considered to be less specific marker
of MTC. The available information directly comparing Ct
and CEA DT is very sparse. Barbet et al. [4] found that
progression rates for Ct and CEA were well correlated,
but Ct DT had greater prognostic value compared to
CEA DT in multivariate analysis. On the contrary, Meijer
et al. [6] in their meta-analysis found CEA DT to have
more pronounced impact on the prognosis, but as pre-
viously mentioned their CEA DT results were obtained
in a small group of patients. Our results suggest that Ct
DT has indeed a greater prognostic value, but we found
also that the classification based upon less-favorable DT
had even greater prognostic meaning. This can be the
result of the presence of the second, less differentiated
MTC cell population, which produce preferentially CEA
with short DT in addition to primary more differentiated
one which is responsible for more stable Ct elevation
with longer DT.
The reliable DT assessment require several marker
serum level measurements spanning through sufficiently
long period (optimally more than 2 years) without any
therapeutic intervention. Optimally, the estimation should
be performed using the same method, preferably in the
same laboratory. This condition was fulfilled in our
patients. In order to use it, one should not delay the serial
Ct and CEA measurements after surgery. According to
Brauckhoff et al. [7], reliable Ct assessments are obtained
one month after thyroidectomy in almost every patient.
Notably, in high-risk patients, with short DT, we can
obtain reliable DT estimation much more earlier - after
one or two DTs, so when the post-surgery Ct or CEA con-
centration is elevated, subsequent measurements should
be taken in relatively short intervals, e.g. 1, then 2 and
4 months, adjusted if necessary, to reveal such high-risk
individuals and consider possible treatment options. In
patients with postsurgery markers’ concentrations within
normal range it is reasonable to take the next measure-
ments every 3 to 6 months, depending on the stage and
time elapsed from surgery. Even in the worst case sce-
nario, when post-surgery Ct is 9.9 pg/ml and DT is 1.32
months (the lowest observed value in our group), after
that time we get Ct around 233 pg/ml - the concentration
at which the identification of metastatic lesion by imaging
methods is still unlikely.
Conclusions
The calcitonin and carcinembrional antigen doubling
times of less than two years are negative prognostic fac-
tors for MTC recurrence-free and total survival in
patients with persistent or recurrent disease. They may
be used as predictive factors for more intensive search
of disease localization in asymptomatic hypercalcitonine-
mia and for therapy choice in symptomatic disease.
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